← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Emmyon, Inc.
Rochester, MN
$6,602,479
Total funding
7
Grants
Funding over time
peak $1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,602,479 · 7
By mechanism
R44$5,992,477 · 4
R43$385,002 · 2
R41$225,000 · 1
Investigators at Emmyon, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of novel therapeutics for obesity and type 2 diabetes$1,021,719
R44 · FY2025 · DK
Development of novel therapeutics for cancer cachexia$997,245
R44 · FY2024 · CA
Development of novel therapeutics for cancer cachexia$990,411
R44 · FY2023 · CA
Development of Novel Small Molecule Therapies for Skeletal Muscle Atrophy$746,147
R44 · FY2018 · AG
Development of Novel Small Molecule Therapies for Skeletal Muscle Atrophy$746,147
R44 · FY2019 · AG
Discovery of Novel Pharmaceutical Agents for Skeletal Muscle Atrophy$745,404
R44 · FY2020 · AR
Discovery of Novel Pharmaceutical Agents for Skeletal Muscle Atrophy$745,404
R44 · FY2021 · AR
Development of Novel Small Molecule Therapies for Skeletal Muscle Atrophy$225,000
R41 · FY2014 · AG
Discovery of Novel Pharmaceutical Agents for Skeletal Muscle Atrophy$225,000
R43 · FY2016 · AR
Development of novel therapies for aging-induced skeletal muscle atrophy.$160,002
R43 · FY2013 · AG